Developer docs
API playgroundTry for free, no card

Search company profiles

GHO Capital

Full company profile

uuid0000ho9

Namestring
GHO Capital
Legal namestring
GHO Capital Partners Advisory Ltd.
Websiteurl
ghocapital.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

GHO Capital (Global Healthcare Opportunities) is a London-headquartered specialist healthcare private equity adviser founded in 2014 by Managing Partners Mike Mortimer, Alan MacKay and Andrea Ponti together with Co-Founders Sir Dennis Gillings and Lady Mireille Gillings. Operating through GHO Capital Partners Advisory Ltd. (FCA-authorised) and GHO Capital Management Limited, the firm manages four flagship private equity funds totalling c. €9 billion of AUM across BioPharma, MedTech, Life Science Tools & Diagnostics, Advisory & Data and HealthTech, and has built 19 transatlantic/global platforms supported by 70+ strategic add-ons across 200+ international locations.

The firm's core "product" is its specialist healthcare investment platform: a thematic sub-sector origination model, an operating playbook covering internationalisation, M&A and organisational build-out, and an embedded network of Operating Partners, Senior Advisers and a Purpose Advisory Council that supports portfolio companies across the healthcare value chain. Recent and current portfolio companies include Scientist.com (AI R&D orchestration), FotoFinder Systems (AI dermoscopy and skin imaging), Sapio Sciences (lab informatics), Alcami Corporation (CDMO), Avid Bioservices (biologics CDMO), Velocity Clinical Research (clinical trial sites), RoslinCT (cell and gene therapy CDMO), ELIQUENT Life Sciences (regulatory and quality consulting) and ClearView Healthcare Partners (pharmaceutical strategic consulting), with exits including Biocare Medical ($950m sale to Agilent Technologies), VISUfarma (sale to Lupin), BioAgilytix, DDC, Quotient Sciences and Caprion Biosciences.

GHO makes money through traditional private equity economics — recurring fund management and advisory fees charged on committed and invested capital across Funds I–IV, supplemented by performance-based carried interest on successful exits. Capital is raised from more than 50 institutional limited partners globally (pension funds, insurance funds, sovereign wealth funds, financial institutions, endowments and family offices), with Fund IV adding over 30 new institutional investors across Europe, North America, Asia-Pacific and the Middle East. Distribution is relationship-driven: senior partner-led origination for portfolio investments, direct institutional LP engagement, and placement-agent-supported fundraising (Rede Partners advised on Fund IV). In May 2026 GHO signed a definitive agreement to merge with Singapore-based CBC Group, creating the world's largest dedicated healthcare investment manager with over US$21 billion in combined AUM across 13 offices and 200+ professionals, expected to close in early 2027; the combined firm intends to expand into private credit and real estate strategies in addition to private equity.

Short descriptiontext

GHO Capital is a London-headquartered specialist healthcare private equity adviser managing c. €9 billion of AUM across four flagship funds, investing in BioPharma, MedTech, Life Science Tools & Diagnostics, Advisory & Data and HealthTech for more than 50 institutional LPs worldwide.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
healthcare private equity, investment advisory services, biopharma investment, medtech investment, asset management
Industry2 codes
PRIMARYFSANAGAA
Primary Fund-of-Funds (Blind-pool FoF)
Financial & Insurance/Private Equity & Venture Capital/Fund-of-Funds / Multi-Manager Platforms
SECONDARYFSANAGAE
Growth Equity Fund-of-Funds
Financial & Insurance/Private Equity & Venture Capital/Fund-of-Funds / Multi-Manager Platforms
NAICS code1 code
  • Portfolio Management and Investment Advice523940
SIC code1 code
  • Investment Advice6282
Product category
Healthcare Private Equity Investment Management
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Fund management and advisory fees
TypeSubscription Recurring
Description

Recurring management and advisory fees charged on committed/invested capital across GHO's flagship private equity funds (Fund I-IV). Capital is raised from more than 50 institutional limited partners globally, including pension funds, insurance funds, sovereign wealth funds, financial institutions, endowments and family offices.

ghocapital.com
2Carried interest / performance fees on fund realizations
TypeManaged Services
Description

Performance-based economics earned upon successful exits of portfolio companies (e.g., Caprion Biosciences, Quotient Sciences, BioAgilytix, DDC, Biocare Medical, VISUfarma) and reinvestment into new platform investments and add-ons.

ghocapital.com
3Co-investment and future private credit / real estate strategies
TypeLicensing Royalties
Description

Across €3bn+ of private equity funds and co-investments managed today; the combined firm with CBC Group intends to offer investors access to private equity, private credit and real estate assets focused on healthcare and life sciences.

ghocapital.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Pricing details1 tier
1Institutional private equity fund commitments and co-investments (terms quote-based / not publicly disclosed)
ModelOtherBilling cadenceMulti-year contract
Notes

Capital commitments accepted from qualified institutional investors; fund-specific economic terms (management fee, carried interest, hurdle) negotiated privately per fund and disclosed in fund documents, not on the public website.

ghocapital.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 6 records shown
1Scientist.com
Description

AI-enabled R&D orchestration platform for life sciences, owned by GHO Capital portfolio.

ghocapital.com
+5 more records
Core offering1 text field

GHO Capital (Global Healthcare Opportunities) is a specialist healthcare investment advisor and private equity fund manager headquartered in London. It raises and manages flagship healthcare-focused private equity funds (Funds I–IV, with Fund IV closing at over €2.5 billion in October 2025), invests in founder-owned and mid-market healthcare companies across Europe and North America, and supports portfolio growth through an embedded Operating Partners network and a transatlantic scaling playbook.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Caprion Biosciences: 85% growth in bookings and growth from 95 to 280 FTEs over three-year hold; 3 bolt-on acquisitions added 5 new geographies.
+5 more records
Product overview1 text field

GHO Capital is a specialist healthcare private equity firm (not a software product company) offering a unified platform-plus-modules investment proposition. At its core is the GHO Capital Investment Funds platform — Flagship Funds I through IV managed by GHO Capital Management Limited and advised by FCA-authorised GHO Capital Partners Advisory Ltd., targeting healthcare subsectors (BioPharma, MedTech, Advisory & Data, Life Science Tools & Diagnostics, HealthTech). Layered on top are specialist investment advisory services (transatlantic platform building, M&A execution, operational enhancement) and supporting infrastructure including the eFrontCloud-hosted GHO Capital Investor Portal and the public Insights/News publishing site. The portfolio companies themselves (e.g., Scientist.com as an AI-powered R&D orchestration platform; FotoFinder with AI dermatoscopes; Sapio Sciences as a unified LIMS/ELN/SDMS informatics platform; Alcami as a CDMO) function as named modules/operating businesses within the firm's investment offering.

Product and service2 records
1GHO Capital Investment Funds (Funds I–IV)
CategoryInvestment vehicles (private equity funds)
Description

Flagship private equity funds offered to institutional limited partners (pension funds, insurance funds, sovereign wealth funds, financial institutions, endowments, family offices) for investment into European and transatlantic healthcare opportunities across BioPharma, MedTech, Advisory & Data, Life Science Tools & Diagnostics and HealthTech sub-sectors.

2Specialist Healthcare Investment Advisory
CategoryInvestment advisory service
Description

Specialist healthcare investment advisory services provided to portfolio companies and limited partners, covering sector-specialist due diligence, transatlantic platform building, M&A execution, internationalisation support and operational enhancement for mid-market and founder-owned healthcare businesses in Europe and North America.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierFlagship — Transformational Merger To Create The World'S Largest Dedicated Healthcare Investment ManagerTypeStrategic or Co-development PartnerAnnounced on2026-05-20
Description

CBC Group (Singapore-headquartered Asian healthcare-focused asset manager) signed a definitive agreement with GHO Capital to merge, creating the world's largest dedicated healthcare investment manager with over US$21 billion in combined AUM. Combined firm will have 200+ professionals across 13 offices in North America, Europe and Asia-Pacific. Mike Mortimer (GHO) and Fu Wei (CBC) will serve as Co-CEOs; Andrea Ponti and Alan MacKay (GHO Co-Founders) take board oversight roles for finance and governance respectively; Board co-chaired by Lady Mireille Gillings (GHO) and Fu Wei. Existing funds continue under their current mandates; transaction expected to close in early 2027 subject to regulatory approvals.

Strategic tierCore — Strategic Buyer Of Biocare Medical Portfolio CompanyTypeStrategic or Co-development PartnerAnnounced on2026-03-09
Description

Agilent Technologies (NYSE:A) agreed to acquire Biocare Medical from Excellere Partners and GHO Capital in an all-cash transaction valued at $950 million. Biocare specialises in immunohistochemistry (IHC), in situ hybridisation (ISH) and fluorescence in situ hybridisation (FISH); Agilent will integrate Biocare into its Life Sciences and Diagnostics Markets Group to expand cancer diagnostics capabilities.

Strategic tierMinor — Portfolio-Level Transaction With ArdenaTypeStrategic or Co-development PartnerAnnounced on2025-11-20
Description

Ardena (GHO portfolio company) signed an agreement to acquire an advanced drug product manufacturing facility from Catalent, expanding Ardena's US footprint. The deal is conducted at the portfolio-company level rather than directly between GHO and Catalent.

Strategic tierCore — Strategic Buyer Of Visufarma Portfolio CompanyTypeStrategic or Co-development PartnerAnnounced on2025-09-29
Description

India-headquartered global pharmaceutical major Lupin Limited (through wholly owned subsidiary Nanomi B.V.) signed a definitive agreement to acquire VISUfarma from GHO Capital, with the deal closed on 2 April 2026. VISUfarma brought €48m 2024 revenue and €53m 2025 revenue across Italy, UK, Spain, Germany and France with 60+ branded ophthalmology products, expanding Lupin's European specialty ophthalmology footprint.

Strategic tierStrategic — Governance And Responsible Investing OversightTypeOthersAnnounced on2023-01-01
Description

Independent cross-industry panel supporting GHO Capital's responsible investing strategy, comprising Dame Caroline Mason (CEO Esmée Fairbairn; Chair), Dr. Lisa Hehenberger (Esade Center for Social Impact), Clarke Murphy (former CEO Russell Reynolds; Sustainable Leadership author) and Sacha Romanovich (former CEO Grant Thornton), supported by Andrea Ponti and Robert Saltrick from GHO. The Council supports Funds II, III and IV and reports to the firm formally at least annually.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

European private equity firm (formerly Edmond de Rothschild Investment Partners) with dedicated Life Sciences and Healthcare activities. Closely comparable to GHO as a European-based healthcare specialist mid-market PE manager.

TypeBroad incumbent
Description

European-headquartered global private equity firm with healthcare as a core sector. Comparable to GHO in mid-market healthcare deal-making but offers a broader sector mandate including industrials, consumer and TMT.

TypeDirect peer
Description

US-based specialist healthcare and life sciences private equity firm. Directly comparable to GHO as a sector-specialist mid-market PE; co-invests with GHO in Alcami Corporation and Avid Bioservices.

TypeDirect peer
Description

US healthcare-focused private equity firm investing in middle-market healthcare companies across services, products and technology. Comparable to GHO as a healthcare specialist PE with a similar sub-sector breadth and mid-market focus.

TypeDirect peer
Description

US-based healthcare-focused private equity firm targeting middle-market pharma, medical products and healthcare services. Directly comparable to GHO as a healthcare specialist PE manager in the transatlantic mid-market.

TypeDirect peer
Description

European (Lyon-headquartered) private equity firm exclusively dedicated to healthcare, investing across medical products, services and life sciences. Directly comparable to GHO as a pure-play European healthcare specialist PE manager.

7The Vistria Group
TypeDirect peer
Description

US private equity firm with a dedicated healthcare practice. Comparable to GHO as a mid-market investor in healthcare; co-invested alongside GHO in the Alcami Corporation acquisition.

TypeDirect peer
Description

Denver-based private equity firm focused on healthcare and other specialised sectors. Directly comparable to GHO as a healthcare-focused PE; co-owned Biocare Medical with GHO and jointly sold the business to Agilent Technologies for $950m.

9EQT Life Sciences
TypeBroad incumbent
Description

European private equity firm with a dedicated Life Sciences vertical within a broad multi-strategy platform. Comparable to GHO as a European PE with specialist healthcare exposure, though operating within a much larger and more diversified GP platform.

TypeBroad incumbent
Description

Global private equity firm with a dedicated Healthcare practice. Comparable to GHO in healthcare sub-sector breadth and European mid-market activity, but operates as a generalist across technology, services and consumer as well.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries21 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A19 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment7 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

GHO Capital

Healthcare Private Equity Investment Managementghocapital.com

GHO Capital is a London-headquartered specialist healthcare private equity adviser managing c. €9 billion of AUM across four flagship funds, investing in BioPharma, MedTech, Life Science Tools & Diagnostics, Advisory & Data and HealthTech for more than 50 institutional LPs worldwide.

What GHO Capital does

GHO Capital (Global Healthcare Opportunities) is a London-headquartered specialist healthcare private equity adviser founded in 2014 by Managing Partners Mike Mortimer, Alan MacKay and Andrea Ponti together with Co-Founders Sir Dennis Gillings and Lady Mireille Gillings. Operating through GHO Capital Partners Advisory Ltd. (FCA-authorised) and GHO Capital Management Limited, the firm manages four flagship private equity funds totalling c. €9 billion of AUM across BioPharma, MedTech, Life Science Tools & Diagnostics, Advisory & Data and HealthTech, and has built 19 transatlantic/global platforms supported by 70+ strategic add-ons across 200+ international locations.

The firm's core "product" is its specialist healthcare investment platform: a thematic sub-sector origination model, an operating playbook covering internationalisation, M&A and organisational build-out, and an embedded network of Operating Partners, Senior Advisers and a Purpose Advisory Council that supports portfolio companies across the healthcare value chain. Recent and current portfolio companies include Scientist.com (AI R&D orchestration), FotoFinder Systems (AI dermoscopy and skin imaging), Sapio Sciences (lab informatics), Alcami Corporation (CDMO), Avid Bioservices (biologics CDMO), Velocity Clinical Research (clinical trial sites), RoslinCT (cell and gene therapy CDMO), ELIQUENT Life Sciences (regulatory and quality consulting) and ClearView Healthcare Partners (pharmaceutical strategic consulting), with exits including Biocare Medical ($950m sale to Agilent Technologies), VISUfarma (sale to Lupin), BioAgilytix, DDC, Quotient Sciences and Caprion Biosciences.

GHO makes money through traditional private equity economics — recurring fund management and advisory fees charged on committed and invested capital across Funds I–IV, supplemented by performance-based carried interest on successful exits. Capital is raised from more than 50 institutional limited partners globally (pension funds, insurance funds, sovereign wealth funds, financial institutions, endowments and family offices), with Fund IV adding over 30 new institutional investors across Europe, North America, Asia-Pacific and the Middle East. Distribution is relationship-driven: senior partner-led origination for portfolio investments, direct institutional LP engagement, and placement-agent-supported fundraising (Rede Partners advised on Fund IV). In May 2026 GHO signed a definitive agreement to merge with Singapore-based CBC Group, creating the world's largest dedicated healthcare investment manager with over US$21 billion in combined AUM across 13 offices and 200+ professionals, expected to close in early 2027; the combined firm intends to expand into private credit and real estate strategies in addition to private equity.

GHO Capital firmographics

Firmographics
Name
GHO Capital
Legal name
GHO Capital Partners Advisory Ltd.
Website
https://ghocapital.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
51–100 employees
Short description
GHO Capital is a London-headquartered specialist healthcare private equity adviser managing c. €9 billion of AUM across four flagship funds, investing in BioPharma, MedTech, Life Science Tools & Diagnostics, Advisory & Data and HealthTech for more than 50 institutional LPs worldwide.
Ownership category
akta.pro rank

GHO Capital industry classification

Industry
Product category
Healthcare Private Equity Investment Management
NAICS
Portfolio Management and Investment Advice (523940)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAGAA
Primary Fund-of-Funds (Blind-pool FoF)
Financial & Insurance/Private Equity & Venture Capital/Fund-of-Funds / Multi-Manager Platforms
SECONDARYFSANAGAE
Growth Equity Fund-of-Funds
Financial & Insurance/Private Equity & Venture Capital/Fund-of-Funds / Multi-Manager Platforms

Keywords

  • Healthcare private equity
  • Investment advisory services
  • Biopharma investment
  • Medtech investment
  • Asset management

Where GHO Capital is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

GHO Capital business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Fund management and advisory fees: Recurring management and advisory fees charged on committed/invested capital across GHO's flagship private equity funds (Fund I-IV). Capital is raised from more than 50 institutional limited partners globally, including pension funds, insurance funds, sovereign wealth funds, financial institutions, endowments and family offices.
  2. Carried interest / performance fees on fund realizations: Performance-based economics earned upon successful exits of portfolio companies (e.g., Caprion Biosciences, Quotient Sciences, BioAgilytix, DDC, Biocare Medical, VISUfarma) and reinvestment into new platform investments and add-ons.
  3. Co-investment and future private credit / real estate strategies: Across €3bn+ of private equity funds and co-investments managed today; the combined firm with CBC Group intends to offer investors access to private equity, private credit and real estate assets focused on healthcare and life sciences.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractInstitutional private equity fund commitments and co-investments (terms quote-based / not publicly disclosed)

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

GHO Capital product offering

Product offering

Core offering

GHO Capital (Global Healthcare Opportunities) is a specialist healthcare investment advisor and private equity fund manager headquartered in London. It raises and manages flagship healthcare-focused private equity funds (Funds I–IV, with Fund IV closing at over €2.5 billion in October 2025), invests in founder-owned and mid-market healthcare companies across Europe and North America, and supports portfolio growth through an embedded Operating Partners network and a transatlantic scaling playbook.

Product overview

GHO Capital is a specialist healthcare private equity firm (not a software product company) offering a unified platform-plus-modules investment proposition. At its core is the GHO Capital Investment Funds platform — Flagship Funds I through IV managed by GHO Capital Management Limited and advised by FCA-authorised GHO Capital Partners Advisory Ltd., targeting healthcare subsectors (BioPharma, MedTech, Advisory & Data, Life Science Tools & Diagnostics, HealthTech). Layered on top are specialist investment advisory services (transatlantic platform building, M&A execution, operational enhancement) and supporting infrastructure including the eFrontCloud-hosted GHO Capital Investor Portal and the public Insights/News publishing site. The portfolio companies themselves (e.g., Scientist.com as an AI-powered R&D orchestration platform; FotoFinder with AI dermatoscopes; Sapio Sciences as a unified LIMS/ELN/SDMS informatics platform; Alcami as a CDMO) function as named modules/operating businesses within the firm's investment offering.

Differentiator

Problem solved

Functional benefit

Brands

  • Scientist.com: AI-enabled R&D orchestration platform for life sciences, owned by GHO Capital portfolio.
  • FotoFinder Systems
  • VISUfarma
  • Sapio Sciences
  • BioAgilytix
  • Caprion Biosciences

Products and services

  • GHO Capital Investment Funds (Funds I–IV) Flagship private equity funds offered to institutional limited partners (pension funds, insurance funds, sovereign wealth funds, financial institutions, endowments, family offices) for investment into European and transatlantic healthcare opportunities across BioPharma, MedTech, Advisory & Data, Life Science Tools & Diagnostics and HealthTech sub-sectors.
  • Specialist Healthcare Investment Advisory Specialist healthcare investment advisory services provided to portfolio companies and limited partners, covering sector-specialist due diligence, transatlantic platform building, M&A execution, internationalisation support and operational enhancement for mid-market and founder-owned healthcare businesses in Europe and North America.

Quantifiable outcome

  • Caprion Biosciences: 85% growth in bookings and growth from 95 to 280 FTEs over three-year hold; 3 bolt-on acquisitions added 5 new geographies.
  • +5 more outcomes

Companies that use GHO Capital

Customer profile

Segments3 records

Ideal customer profiles2 records

GHO Capital technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

GHO Capital partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered flagship — transformational merger to create the world's largest dedicated healthcare investment manager, core — strategic buyer of biocare medical portfolio company, minor — portfolio-level transaction with ardena, core — strategic buyer of visufarma portfolio company and strategic — governance and responsible investing oversight.

  • CBC Groupflagship — transformational merger to create the world's largest dedicated healthcare investment managerStrategic or Co-development Partner · 20 May 2026CBC Group (Singapore-headquartered Asian healthcare-focused asset manager) signed a definitive agreement with GHO Capital to merge, creating the world's largest dedicated healthcare investment manager with over US$21 billion in combined AUM. Combined firm will have 200+ professionals across 13 offices in North America, Europe and Asia-Pacific. Mike Mortimer (GHO) and Fu Wei (CBC) will serve as Co-CEOs; Andrea Ponti and Alan MacKay (GHO Co-Founders) take board oversight roles for finance and governance respectively; Board co-chaired by Lady Mireille Gillings (GHO) and Fu Wei. Existing funds continue under their current mandates; transaction expected to close in early 2027 subject to regulatory approvals.
  • Agilent Technologiescore — strategic buyer of biocare medical portfolio companyStrategic or Co-development Partner · 9 March 2026Agilent Technologies (NYSE:A) agreed to acquire Biocare Medical from Excellere Partners and GHO Capital in an all-cash transaction valued at $950 million. Biocare specialises in immunohistochemistry (IHC), in situ hybridisation (ISH) and fluorescence in situ hybridisation (FISH); Agilent will integrate Biocare into its Life Sciences and Diagnostics Markets Group to expand cancer diagnostics capabilities.
  • Catalent (Ardena US footprint deal)minor — portfolio-level transaction with ardenaStrategic or Co-development Partner · 20 November 2025Ardena (GHO portfolio company) signed an agreement to acquire an advanced drug product manufacturing facility from Catalent, expanding Ardena's US footprint. The deal is conducted at the portfolio-company level rather than directly between GHO and Catalent.
  • Lupin Limitedcore — strategic buyer of visufarma portfolio companyStrategic or Co-development Partner · 29 September 2025India-headquartered global pharmaceutical major Lupin Limited (through wholly owned subsidiary Nanomi B.V.) signed a definitive agreement to acquire VISUfarma from GHO Capital, with the deal closed on 2 April 2026. VISUfarma brought €48m 2024 revenue and €53m 2025 revenue across Italy, UK, Spain, Germany and France with 60+ branded ophthalmology products, expanding Lupin's European specialty ophthalmology footprint.
  • Purpose Advisory Council (chaired by Dame Caroline Mason)strategic — governance and responsible investing oversightOthers · 1 January 2023Independent cross-industry panel supporting GHO Capital's responsible investing strategy, comprising Dame Caroline Mason (CEO Esmée Fairbairn; Chair), Dr. Lisa Hehenberger (Esade Center for Social Impact), Clarke Murphy (former CEO Russell Reynolds; Sustainable Leadership author) and Sacha Romanovich (former CEO Grant Thornton), supported by Andrea Ponti and Robert Saltrick from GHO. The Council supports Funds II, III and IV and reports to the firm formally at least annually.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

GHO Capital competitors and assessment

Company assessment

Direct peers

  • Andera Partners: European private equity firm (formerly Edmond de Rothschild Investment Partners) with dedicated Life Sciences and Healthcare activities. Closely comparable to GHO as a European-based healthcare specialist mid-market PE manager.
  • Ampersand Capital Partners: US-based specialist healthcare and life sciences private equity firm. Directly comparable to GHO as a sector-specialist mid-market PE; co-invests with GHO in Alcami Corporation and Avid Bioservices.
  • Linden Capital Partners: US healthcare-focused private equity firm investing in middle-market healthcare companies across services, products and technology. Comparable to GHO as a healthcare specialist PE with a similar sub-sector breadth and mid-market focus.
  • Avista Capital Partners: US-based healthcare-focused private equity firm targeting middle-market pharma, medical products and healthcare services. Directly comparable to GHO as a healthcare specialist PE manager in the transatlantic mid-market.
  • ArchiMed: European (Lyon-headquartered) private equity firm exclusively dedicated to healthcare, investing across medical products, services and life sciences. Directly comparable to GHO as a pure-play European healthcare specialist PE manager.
  • The Vistria Group: US private equity firm with a dedicated healthcare practice. Comparable to GHO as a mid-market investor in healthcare; co-invested alongside GHO in the Alcami Corporation acquisition.
  • Excellere Partners: Denver-based private equity firm focused on healthcare and other specialised sectors. Directly comparable to GHO as a healthcare-focused PE; co-owned Biocare Medical with GHO and jointly sold the business to Agilent Technologies for $950m.

Broad incumbents

  • BC Partners: European-headquartered global private equity firm with healthcare as a core sector. Comparable to GHO in mid-market healthcare deal-making but offers a broader sector mandate including industrials, consumer and TMT.
  • EQT Life Sciences: European private equity firm with a dedicated Life Sciences vertical within a broad multi-strategy platform. Comparable to GHO as a European PE with specialist healthcare exposure, though operating within a much larger and more diversified GP platform.
  • Apax Partners: Global private equity firm with a dedicated Healthcare practice. Comparable to GHO in healthcare sub-sector breadth and European mid-market activity, but operates as a generalist across technology, services and consumer as well.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

GHO Capital social profiles

Digital presence

GHO Capital compliance and trust

Trust signal

Compliance3 records

GHO Capital financial estimates

Financial estimate

Revenue estimate

Valuation estimate

GHO Capital leadership team

Management profile

Number of profiles

Profiles11 records

GHO Capital subsidiaries and ownership

Company hierarchy

Subsidiaries21 records

GHO Capital funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

GHO Capital M&A and investment

M&A and investment

M&A19 records

Investments7 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GHO Capital

What does GHO Capital do?

GHO Capital (Global Healthcare Opportunities) is a specialist healthcare investment advisor and private equity fund manager headquartered in London. It raises and manages flagship healthcare-focused private equity funds (Funds I–IV, with Fund IV closing at over €2.5 billion in October 2025), invests in founder-owned and mid-market healthcare companies across Europe and North America, and supports portfolio growth through an embedded Operating Partners network and a transatlantic scaling playbook.

Is GHO Capital a public or private company?

GHO Capital is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was GHO Capital founded?

GHO Capital was founded in 2014. It employs 51 to 100 people.

Where is GHO Capital based?

GHO Capital is headquartered in London, United Kingdom, in the Europe region.

How does GHO Capital make money?

Three revenue lines are on record. Fund management and advisory fees are the primary driver. The others are carried interest / performance fees on fund realizations and co-investment and future private credit / real estate strategies.

Who are GHO Capital's main competitors?

Direct peers on record are Andera Partners, Ampersand Capital Partners, Linden Capital Partners, Avista Capital Partners, ArchiMed, The Vistria Group and Excellere Partners. Broad incumbents are BC Partners, EQT Life Sciences and Apax Partners.

Does GHO Capital have an API?

No public API is recorded for GHO Capital.

What industry is GHO Capital in?

GHO Capital's product category is Healthcare Private Equity Investment Management. Its primary akta.pro industry code is FSANAGAA, Primary Fund-of-Funds (Blind-pool FoF), with a secondary code of FSANAGAE, Growth Equity Fund-of-Funds. Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0GHO Capital Names Vivid Sehgal As Operating PartnerGHO Capital appointed Vivid Sehgal as Operating Partner, bringing over 30 years of healthcare and life sciences leadership. He will focus on scaling businesses and transformation, and the appointment comes as GHO prepares for its merger with CBC Group, expected to close in early 2027.AInvestThe real signal in GHO Capital's operating-partner hiresGHO Capital hired Vivid Sehgal as an operating partner, continuing its pattern of adding healthcare operators. The firm's $21B merger with CBC Group and €9B in assets under management frame the strategy, with LivaNova's 30% gain as a proof point. Investors are urged to judge future portfolio companies on fundamentals rather than fund size.Straits ResearchDigital Dermatoscopes: Imaging Devices & Connected DermatologyThe digital dermatoscopy market is evolving toward smartphone-connected and AI-integrated systems to address rising melanoma cases, with recent regulatory approvals and funding rounds highlighting key industry developments. Notable events include DermaSensor securing a CE Mark and Series B financing, MetaOptima receiving government support for its AI imaging system, and GHO Capital acquiring a majority stake in FotoFinder Systems.GlobeNewswireGHO Capital appoints Olav König as Head of Investor RelationsGHO Capital Partners, a London-based specialist healthcare investment firm, has appointed Olav König as Head of Investor Relations. König brings over 25 years of private markets experience, including more than a decade as Head of EMEA Investor Relations at HarbourVest Partners. The appointment follows GHO's recent announcement of its definitive agreement with CBC Group to create the world's largest dedicated healthcare investment manager, with the transaction expected to close in early 2027.GlobeNewswireExcellere Partners and GHO Capital complete sale of Biocare Medical to Agilent TechnologiesExcellere Partners and GHO Capital completed the sale of Biocare Medical to Agilent Technologies on June 25, 2026. Under private equity ownership, Biocare achieved annual double-digit revenue and profitability growth, expanded into molecular diagnostics, and became a recognized leader in immunohistochemistry, in situ hybridization, and fluorescence in situ hybridization solutions. The acquisition combines two strategically aligned businesses expected to unlock greater market access, enhanced customer support, and accelerated innovation for Biocare's customers worldwide.The Business TimesHealthcare is sector least affected by geopolitical tensions, say CBC Group and GHO Capital after US$21 billion mergerCBC Group and GHO Capital are merging to create the world's largest dedicated healthcare investment manager with US$21 billion in assets under management, with the deal expected to complete next year after more than 18 months of negotiations. The combined entity will be co-led by both CEOs and will have presence across the three major healthcare markets of Asia, the US, and Europe, bringing together approximately 200 professionals. CBC Group CEO Fu Wei noted that healthcare is minimally affected by geopolitical tensions due to its universal nature, positioning the merger as a strategic move to capitalize on global healthcare opportunities.Pulse 2.0GHO Capital And CBC Group: $21 Billion Merger To Create Major Healthcare Investment FirmGlobal Healthcare Opportunities (GHO) and CBC Group have signed a definitive agreement to merge, creating the world’s largest dedicated healthcare investment manager with more than $21 billion in combined assets under management. The combined firm will operate across 13 offices in North America, Europe, and Asia-Pacific with over 200 investment professionals, serving portfolio companies in pharmaceuticals, medical devices, diagnostics, healthcare infrastructure, and life sciences. The transaction is expected to close in early 2027, subject to regulatory approvals, with Mike Mortimer and Fu Wei serving as Co-Chief Executives of the new organization.The HinduGHO Capital and CBC Group to Create World’s Largest Dedicated Healthcare Investment FirmGHO Capital, a European specialist healthcare investor headquartered in London, and CBC Group, an Asian healthcare-focused asset manager headquartered in Singapore, have signed a definitive agreement to create the world's largest dedicated healthcare investment manager, with combined assets under management exceeding USD 21 billion. The new firm will operate across 13 offices with over 200 investment and operating professionals spanning North America, Europe, and Asia-Pacific, collectively accounting for approximately 90% of global healthcare R&D spend. The combined entity will be co-led by GHO Co-Founder Mike Mortimer and CBC Founder Fu Wei, with the transaction expected to close in early 2027 pending regulatory approvals.MedCity NewsGHO Capital, CBC Group Combine to Form $21B Healthcare Investment GiantTwo large healthcare investment firms, GHO Capital and CBC Group, announced a merger to create a $21 billion assets under management investment firm, making it the world's largest dedicated healthcare investment platform. The new firm aims to enhance its global reach and support healthcare companies across various stages and regions. The deal is expected to close early next year pending regulatory approvals.